Neurocrine Biosciences (NBIX) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $165.82 +0.59%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of ($0.07), $0.10 better than the analyst estimate of ($0.17).
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neurocrine Bio. (NBIX) PT Raised to $224 at Guggenheim
- L.B. Foster (FSTR) Reports In-Line Q3 EPS ; Offers Guidance
- XPEL, Inc. (XPEL) Tops Q3 EPS by 4c, Misses on Revenue; Offers Q4 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
